Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.

BACKGROUND:The diagnostic performance of indocyanine green (ICG) fluorescence-guided sentinel lymph node biopsy (SLNB) for the presence of metastases in breast cancer remains unclear. OBJECTIVE:We performed a meta-analysis to investigate the diagnostic performance of ICG-guided SLNB. METHODS:Eligibl...

Full description

Bibliographic Details
Main Authors: Xiaohui Zhang, Yan Li, Yidong Zhou, Feng Mao, Yan Lin, Jinghong Guan, Qiang Sun
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4900647?pdf=render
id doaj-3d2b8f207012439e862a462694a544b6
record_format Article
spelling doaj-3d2b8f207012439e862a462694a544b62020-11-25T02:10:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01116e015559710.1371/journal.pone.0155597Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.Xiaohui ZhangYan LiYidong ZhouFeng MaoYan LinJinghong GuanQiang SunBACKGROUND:The diagnostic performance of indocyanine green (ICG) fluorescence-guided sentinel lymph node biopsy (SLNB) for the presence of metastases in breast cancer remains unclear. OBJECTIVE:We performed a meta-analysis to investigate the diagnostic performance of ICG-guided SLNB. METHODS:Eligible studies were identified from searches of the databases PubMed and EMBASE up to September 2015. Studies that reported the detection rate of ICG fluorescence-guided SLNB with full axillary lymph node dissection and histological or immunohistochemical examinations were included. A meta-analysis was performed to generate pooled detection rate, sensitivity, specificity, false negative rate, diagnostic odds ratio (DOR) and a summary receiver operator characteristic curve (SROC). RESULTS:Nineteen published studies were included to generate a pooled detection rate, comprising 2594 patients. The pooled detection rate was 0.98 (95% confidence interval [CI], 0.96-0.99). Six studies finally met the criteria for meta-analysis, which yielded a pooled sensitivity of 0.92 (95% CI, 0.85-0.96), specificity 1 (95% CI, 0.97-1), and DOR 311.47 (95% CI, 84.11-1153.39). The area under the SROC was 0.9758. No publication bias was found. CONCLUSION:ICG fluorescence-guided SLNB is viable for detection of lymph node metastases in breast cancer. Large-scale randomized multi-center trials are necessary to confirm our results.http://europepmc.org/articles/PMC4900647?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Xiaohui Zhang
Yan Li
Yidong Zhou
Feng Mao
Yan Lin
Jinghong Guan
Qiang Sun
spellingShingle Xiaohui Zhang
Yan Li
Yidong Zhou
Feng Mao
Yan Lin
Jinghong Guan
Qiang Sun
Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.
PLoS ONE
author_facet Xiaohui Zhang
Yan Li
Yidong Zhou
Feng Mao
Yan Lin
Jinghong Guan
Qiang Sun
author_sort Xiaohui Zhang
title Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.
title_short Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.
title_full Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.
title_fullStr Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.
title_full_unstemmed Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.
title_sort diagnostic performance of indocyanine green-guided sentinel lymph node biopsy in breast cancer: a meta-analysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description BACKGROUND:The diagnostic performance of indocyanine green (ICG) fluorescence-guided sentinel lymph node biopsy (SLNB) for the presence of metastases in breast cancer remains unclear. OBJECTIVE:We performed a meta-analysis to investigate the diagnostic performance of ICG-guided SLNB. METHODS:Eligible studies were identified from searches of the databases PubMed and EMBASE up to September 2015. Studies that reported the detection rate of ICG fluorescence-guided SLNB with full axillary lymph node dissection and histological or immunohistochemical examinations were included. A meta-analysis was performed to generate pooled detection rate, sensitivity, specificity, false negative rate, diagnostic odds ratio (DOR) and a summary receiver operator characteristic curve (SROC). RESULTS:Nineteen published studies were included to generate a pooled detection rate, comprising 2594 patients. The pooled detection rate was 0.98 (95% confidence interval [CI], 0.96-0.99). Six studies finally met the criteria for meta-analysis, which yielded a pooled sensitivity of 0.92 (95% CI, 0.85-0.96), specificity 1 (95% CI, 0.97-1), and DOR 311.47 (95% CI, 84.11-1153.39). The area under the SROC was 0.9758. No publication bias was found. CONCLUSION:ICG fluorescence-guided SLNB is viable for detection of lymph node metastases in breast cancer. Large-scale randomized multi-center trials are necessary to confirm our results.
url http://europepmc.org/articles/PMC4900647?pdf=render
work_keys_str_mv AT xiaohuizhang diagnosticperformanceofindocyaninegreenguidedsentinellymphnodebiopsyinbreastcancerametaanalysis
AT yanli diagnosticperformanceofindocyaninegreenguidedsentinellymphnodebiopsyinbreastcancerametaanalysis
AT yidongzhou diagnosticperformanceofindocyaninegreenguidedsentinellymphnodebiopsyinbreastcancerametaanalysis
AT fengmao diagnosticperformanceofindocyaninegreenguidedsentinellymphnodebiopsyinbreastcancerametaanalysis
AT yanlin diagnosticperformanceofindocyaninegreenguidedsentinellymphnodebiopsyinbreastcancerametaanalysis
AT jinghongguan diagnosticperformanceofindocyaninegreenguidedsentinellymphnodebiopsyinbreastcancerametaanalysis
AT qiangsun diagnosticperformanceofindocyaninegreenguidedsentinellymphnodebiopsyinbreastcancerametaanalysis
_version_ 1724919373710229504